For citations:
Brose M.S., Panaseykin Yu., Konda B., de la Fouchardiere C., Hughes B.G., Gianoukakis A.G., Park Y.J., Romanov I., Krzyzanowska M.K., Leboulleux S., Binder T.A., Dutcus C., Xie R., Taylor M.H. A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer. Head and Neck Tumors (HNT). 2022;12(1):86-98. (In Russ.) https://doi.org/10.17650/2222-1468-2022-12-1-86-98
Email this article 